Skip to main content

Table 2 Baseline demographic data of the groups either receiving or not receiving plasma exchange (PEX) as part of disease induction

From: Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service

Characteristic No PEX (n = 46) PEX (n = 58) p value
Age (years) 61 ± 15 60 ± 17 0.81
Male / Female 26 / 20 27 / 31 -
ANCA status (%)    
PR3+ 26 (57) 25 (43) 0.67
MPO+ 16 (35) 30 (52) 0.07
Negative 4 (8) 3 (5) 0.81
Diagnosis    
GPA 26 25 0.67
MPA 12 29 0.02
ANCA- vasculitis 4 3 0.81
EGPA 3 1 0.32
Organ involvement    
Number (%) of patients    
Kidney 35 (76) 57 (98) 0.47
Lung 26 (46) 30 (52) 0.54
ENT 17 (37) 13 (22) 0.89
Nerve 14 (30) 8 (14) 0.03
Skin 10 (22) 8 (14) 0.26
Joints 7 (15) 11 (19) 0.65
Eye 4 (9) 5 (9) 0.96
Gastrointestinal 1 (2) 3 (5) 0.44
Indication for PEX    
Number (%) of patients    
Dialysis-requiring renal failure - 20 (34)  
Serum creatinine ≥500 μmol/l - 12 (21)a  
Alveolar haemorrhage - 9 (16)  
Histologically significant renal disease - 52 (90)  
BVAS 17 (13 – 23) 29 (12 – 47) 0.01
  1. Abbreviations are as for Table 1. Data are given as number of patients (%) with median and interquartile range shown for BVAS. a10 of these 12 patients required dialysis at disease presentation